London-listed addiction specialist Indivior (LSE: INDV) failed in its bid to block a generic competitor to its Suboxone film (buprenorphine/naloxone) drug, used in the treatment of opioid addiction.
A US court ruled against re-opening proceedings against Indian drugmaker Dr Reddy’s Laboratories (NSE: DRREDDY), which Indivior had wanted to block from selling the copy in the US market.
Indivior is expecting further US competition from privately-owned generics company Alvogen, which has its own copy of Suboxone.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze